Reported 2 days ago
H.C. Wainwright analyst Swayampakula Ramakanth recently assigned a Buy rating to Corcept Therapeutics Incorporated (CORT) with a price target of $145, despite a recent distribution shift for its drug Korlym. While recent changes might delay pharmacy operations, the analyst considers these issues temporary and advises investors to buy on dips, highlighting Corcept’s potential in treating Cushing's syndrome.
Source: YAHOO